posted on 2024-02-29, 03:29authored byBritteny
J. Cassaidy, Brittany A. Moser, Ani Solanki, Qing Chen, Jingjing Shen, Kristen Gotsis, Zoe Lockhart, Nakisha Rutledge, Matthew G. Rosenberger, Yixiao Dong, Delaney Davis, Aaron P. Esser- Kahn
With the emergence
of SARS-CoV-2 and the continued emergence
of
new infectious diseases, there is a need to improve and expand current
vaccine technology. Controlled-release subunit vaccines provide several
benefits over current vaccines on the market, including the use of
less antigen and fewer boost doses. Previously, our group reported
molecules that alter NF-κB signaling improved the vaccine’s
performance and improved adjuvant-related tolerability. In this report,
we test how these immune potentiators will influence responses when
included as part of a controlled-release poly(lactic-co-glycolic) vaccine formulation. Murine in vivo studies revealed that
SN50 and honokiol improved antibody levels at early vaccine time points.
Microparticles with SN50 produced strong antibody levels over a longer
period compared to microparticles without SN50. The same particles
also increased T-cell activity. All of the immune potentiators tested
further promoted Th2 humoral responses already exhibited by the control
CpG OVA microparticle formulation. Overall, under controlled-release
conditions, immune potentiators enhance the existing effects of controlled-release
formulations, making it a potentially beneficial additive for controlled-release
vaccine formulations.